Redwood AI Clinches Terry Fox Research Grant for Oncology AI Platform
Published on 09/23/2026 at 15:31 | Editorial boerse-global.de
A consortium that includes Redwood AI has secured backing from the Digital Health Innovation Fund of the Terry Fox Research Institute to advance SynoGraph, an artificial intelligence platform built for oncology applications. The award, disclosed alongside partner Onco-Innovations Limited, designates Onco-Innovations as the lead applicant while Redwood AI participates as a project partner. Two Canadian scientific institutions round out the group: Canada's Michael Smith Genome Sciences Centre and the Centre de recherche du CHU de Québec–Université Laval.
The funding takes the form of a reimbursement-based grant covering as much as 25 percent of project costs, measured against an estimated total budget of $3.5 million. Redwood AI's contribution to the joint effort centers on supplying and structuring the data that feeds the platform, alongside feature engineering work and responsibilities tied to evaluating physicochemical properties within the platform architecture. Partnering with specialized research bodies is expected to deepen AI-driven data processing in the oncology field, and the institute's decision to release the funds underscores the scientific weight of the initiative.
A Busy Stretch of Corporate Housekeeping
The research award lands amid a series of structural moves Redwood AI has pushed through this year. On August 13, the company completed its full takeover of Quantum.IQ Technologies, folding the acquired business in as a wholly owned subsidiary. The deal carried the issuance of up to 14,033,558 common shares to Quantum.IQ Technologies Inc. shareholders, priced notionally at CAD $2.98 per share. Of that total, 7,033,558 base shares are subject to a staged 24-month escrow period, while as many as 7,000,000 milestone shares are tied to specific customer and revenue targets. The transaction also generated 50,000 shares for administrative fees and 100,000 shares as a finder's fee.
Should investors sell immediately? Or is it worth buying Redwood AI?
More recently, on September 11, the company reported operational adjustments on the service-provider front. It terminated an existing investor relations arrangement and recovered CAD 588,285 in the process, while simultaneously engaging Frontier Media Inc. for corporate communications and market visibility work. That same day, Redwood AI drew a mention from Life Sciences BC, the regional industry organization, which featured the company in its brochure and quarterly newsletter under the Growth Catalyst Program.
US Trading Access Already in Place
Earlier in the year, on May 26, Redwood AI had already smoothed the path for American investors. Its common shares won clearance for electronic clearing and settlement through the Depository Trust Company, a step designed to streamline trade settlement and bolster liquidity in the US market.
Share Price Responds to the Grant News
Investors greeted the SynoGraph award with a firm bid. Redwood AI's stock climbed 11 percent to €1.04, lifting the shares to 28 percent above their 52-week low. The advance marks a sharp turn from the prior session, when the stock closed Tuesday at €0.9220 for a decline of 1.5 percent, leaving it 14 percent beneath its 50-day moving average of €1.08.
With the operational buildout around AI in healthcare still unfolding, market participants are watching how the funded research initiative translates into business momentum over the coming months.
Ad
Redwood AI Stock: New Analysis - 23 September
Fresh Redwood AI information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
